To answer my own question about short, mid and long term growth,
along comes Robert McCormick's take on the three. My other concerns,
cash flow and EPS, right in the next paragraph. These are not
necessarily my opinions, but taken directly from the press release:
biz.yahoo.com
Would appreciate any feedback.
Regards,
Caroline
"In the short-term," continued McCormick, "we believe the company
is strategically positioned to benefit from on-going growth in both
the leg vein and skin resurfacing markets.
"We have received more than 100 orders since the beginning of the
year for our new Aura Laser System, making substantial inroads into
the growing vascular lesion market which includes leg vein treatment.
"We will also begin to market aggressively the newly acquired
Paragon(TM) CO2 Laser, capitalizing on the strategies employed in
our successful roll out of the Aura Laser.
"We believe the company's mid-term opportunities lie in continued
development of the operating room systems business of Heraeus
Surgical," said McCormick, "specifically its ceiling-mounted
equipment management and centralized smoke evacuation (CVAC)
systems.
"Potential changes in the healthcare arena could create considerable
market opportunities for their patented CVAC systems which remove
hazardous airborne debris from the operating room.
"We believe longer term opportunities for the company lie in new
regulatory approvals of photodynamic therapy (PDT), an innovative
cancer treatment that utilizes photosensitive drugs and laser light
to selectively kill diseased cells," said McCormick.
To improve profitability further, Laserscope also said it expects
to incrementally reduce operating expenses of the combined company
such that, in 12 months, operating expenses should be more than $3
million lower than current levels.
|
